AccessibilityHelp

Electra Therapeutics(NASDAQ) ETRA

Market Cap$546.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-34%
5 YearN/A
1 YearN/A
1 Month-31%
$8.35
-4.13%
-0.36Today
After hours$8.30-$0.05 (-0.60%)
Electra Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 8.712026-10-23
Electra Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.46%USD 8.752026-10-16
1 month-31.25%USD 12.672026-09-23
Since inception-34.26%USD 13.252026-09-18

Electra Therapeutics Financials at a Glance

Market Cap

$546.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

9.48 (High)

Price

$8.35

Volume

159,038.811

Open

$8.98

Previous Close

$8.37

Daily Range

$8.26 - $9.18

52-Week Range

$8.26 - $15.50

Estimated Earnings Date

N/A

ETRA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Electra Therapeutics

Electra Therapeutics Inc. is a clinical stage biotechnology company focused on developing innovative therapies targeting diseases in immunology and cancer. Founded in 2018 and headquartered in South San Francisco, the company aims to address unmet medical needs through its cutting-edge research and development efforts.

Products and Services
  • Therapies targeting novel immunology and cancer pathways
  • Clinical trials aimed at evaluating safety and efficacy
  • Collaborations with research institutions for advanced studies
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Potential market expansion as immunotherapy gains traction
  • Strategic partnerships to enhance research capabilities
Financial Highlights
  • Market capitalization of approximately $185.6 million
  • Stock price range between $8.5 and $15.5 over the past year
  • Average trading volume of 831,004 shares, indicating investor interest
Electra Therapeutics Inc. operates in the dynamic field of biotechnology, focusing on therapies that address critical health challenges. The company's commitment to innovation is reflected in its robust pipeline and ongoing clinical trials. With a market capitalization of approximately $185.6 million, Electra is positioned to capitalize on the growing demand for advanced therapies in immunology and cancer. The stock has shown a price range between $8.5 and $15.5 over the past year, suggesting potential for growth. The average trading volume of 831,004 shares indicates a healthy level of investor engagement, highlighting the company's appeal in the biotechnology sector.
AI Generated • Oct 18, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Que Huong Dong, MBA

Website

www.electra-therapeutics.com

Headquarters

South San Francisco, CA 94080, US

ETRA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$546.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.77M

Volume

159.04K

Avg. Volume

681.72K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Electra Therapeutics Performance Analysis

Electra Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Electra Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.39N/A
20252025-12-31USD -0.99150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$546.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,683.28+0.01%
^DJIDJI
$52,354.54+0.00%
^IXICNASDAQ
$26,225.31+0.01%
BTCBitcoin
$80,178.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$12.59-16.95%
EWZiShares - iShares Msci Brazil ETF
$34.15-19.82%
ITUBItaú Unibanco
$7.70-20.37%
XPXP
$15.71-48.36%

Questions About ETRA

What is the current price of Electra Therapeutics?

Electra Therapeutics is trading at $8.37 per share.

What is the 52-week range for Electra Therapeutics?

Over the past 52 weeks, Electra Therapeutics has traded between $8.26 and $15.50.

How much debt does Electra Therapeutics have?

As of the most recent reporting period, Electra Therapeutics reported total debt of $2.09M.

How much cash does Electra Therapeutics have on hand?

Electra Therapeutics reported $33.01M in cash and cash equivalents in its most recent financial results.

What is Electra Therapeutics’s dividend yield?

Electra Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services